Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This dose response study is proposed to explore the extent to which Nexium increases endogenous gastrin concentrations and to assess whether Nexium treatment may be useful in the setting of islet cell transplantation for type 1 diabetes to expand islet cells in vivo after transplant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: City of Hope Medical Center
• Treatments: Esomeprazole; Gastrins

Criteria

Inclusion Criteria:

• age 18-65

• healthy

• free of clinical signs of diabetes, peptic ulcer, liver or kidney disease,autoimmune disease, or any acute chronic infection.

Exclusion Criteria:

• history or clinical signs of diabetes

• history of liver or kidney disease

• positive H-pylori status

• currently using a proton pump inhibitor

• prior hypersensitivity to Nexium

• pregnant or breastfeeding women